First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Details 詳細情報について

• CRID

  1360855569129460736

• DOI

  10.1093/annonc/mdv270

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419317703?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419317703?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/26/9/1883/16701310/mdv270.pdf

• Data Source

  • Crossref